XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies
Article in Molecular Cancer Therapeutics (November 2023)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Molecular Cancer Therapeutics (November 2023)
Article in Nature Reviews Drug Discovery (August 2023)